A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Etrasimod (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Jul 2023 Status changed from recruiting to completed.
- 04 Jan 2023 Planned End Date changed from 1 Oct 2023 to 6 Jun 2023.
- 04 Jan 2023 Planned primary completion date changed from 1 May 2023 to 6 Jun 2023.